Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





First-of-Its-Kind End-to-End Digital Health Platform Automates and Simplifies Diagnostic COVID-19 Testing Experience

By LabMedica International staff writers
Posted on 31 Aug 2021
A new end-to-end digital health platform automates and simplifies diagnostic testing experience by transforming connectivity between clinical labs, providers, and patients, thus creating a testing ecosystem.

PreciseMDX (Palo Alto, CA, USA) has launched a cloud-based solution that automates and simplifies the diagnostic testing experience, empowering labs to deliver a transformative journey to providers and patients. More...
PreciseMDX dramatically improves connectivity between clinical labs, providers, and patients during every step of the diagnostic testing process for any type of test.

The first-of-its-kind platform enables labs of any size to quickly and seamlessly set up rapidly scalable, personalized, digital experiences that providers and patients expect in this post-pandemic era where consumer adoption of virtual care has skyrocketed. The unexpected volume of COVID-19 testing has exposed the costs and risks associated with manual data management. PreciseMDX replaces manual data entry with an automated flexible end-to-end solution that works seamlessly with any LIS or LIMS, allowing labs to scale their business and streamline workflow, resulting in significant time and cost savings.

PreciseMDX is designed to eliminate complexity for all users - from scheduling and check-in to coordinating on-site or at-home testing to results notification and reporting. Labs receive step-by-step user onboarding, and easily customizable test orders management software - all from the cloud, allowing for deployment in days, not weeks or months. The PreciseMDX solution supports any type of diagnostic test, including: women's & men's health (fertility, prenatal, cancer, testosterone), sexual health (STIs, HPV, UTI), wellness/nutrition (nutrition DNA kit, food allergy/intolerances), COVID-19 testing, respiratory, nail fungal wound panels, and vaccines.

"The scramble to ramp up testing during COVID-19, exposed a need in the healthcare industry for an automated diagnostic testing experience so that labs can scale rapidly, patients can have control over the process and receive results quickly, and providers can treat patients quicker with a faster, more connected system," said Mark Dorner, co-Founder & Chief Executive Officer of PreciseMDX. "We saw this need and created a technology to completely transform the diagnostic testing experience to one that is automated, simple, and user friendly. Today, this is what patients expect."

Related Links:
PreciseMDX


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.